Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
Artikel i vetenskaplig tidskrift, 2020
Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.
Acute myeloid leukemia
immunotherapy
IL-2
relapse prevention
histamine dihydrochloride
normal karyotype
Författare
Malin S. Nilsson
Göteborgs universitet
Alexander Hallner
Göteborgs universitet
Mats Brune
Göteborgs universitet
Staffan Nilsson
Göteborgs universitet
Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik
Fredrik B Thorén
Göteborgs universitet
Anna Martner
Göteborgs universitet
Kristoffer Hellstrand
Göteborgs universitet
Human Vaccines and Immunotherapeutics
2164-5515 (ISSN) 2164-554X (eISSN)
Vol. 16 1 109-111Ämneskategorier
Immunologi inom det medicinska området
Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)
Mikrobiologi inom det medicinska området
DOI
10.1080/21645515.2019.1636598
PubMed
31242079